QMA

Enanta Pharmaceuticals, Inc. (ENTA) — QMA analysis

Sector: Healthcare · Market cap: $292M · Price: $11.64 · Data as of 2026-10-23

34
/100
F
Composite grade
Higher score than 12% of 22,734 tracked stocks

Enanta Pharmaceuticals, Inc. has a below-average composite score of 34/100, higher score than 12% of 22,734 tracked stocks. The highest-scoring layer is Analysts / transcripts; the lowest is Earnings quality.

Analytical score, not investment advice. No score is an instruction or a guarantee. Past performance ≠ future results.
Share this analysis
𝕏in

What 10 data layers say about ENTA

The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.

LayerScore
Fundamental value (FVS)30/100
Earnings quality (EQS)20/100
Technical trend (TSS)42/100
Relative strength (RS)27/100
Momentum (USS)40/100
Insider activity (IAS)21/100
Off-exchange trading (FINRA) / large flows (WHS)32/100
News sentiment (NSS)52/100
Analysts / transcripts (ATS)84/100
Catalysts (XS)35/100

What does the QMA model currently show for Enanta Pharmaceuticals, Inc.?

The composite score is an entry point, not a signal. What matters is layer confluence — whether they point the same direction.

For ENTA the layers diverge — some score high (Analysts / transcripts), others low (Earnings quality). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.

ENTA insider & smart money activity

Over the recent period we record 6 reported insider purchases and 0 sales for ENTA: only reported purchases, no sales. A description of the data layer, not an instruction.

How ENTA compares

Similar stocks from the same sector:

Frequently asked questions

What is the composite score for ENTA stock?

34/100 (grade F) as of 2026-10-23, fusing 10 data layers. An analytical score, not advice.

Are insiders buying ENTA stock?

Over the recent period, reported: purchases 6, sales 0 (purchases $1.7M). Insider activity: only reported purchases, no sales — a description of reported data, not a trade instruction.

Where can I see live ENTA data?

Live ENTA data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.

Explore more — for free

The ENTA score is just the start. Keep going free in the QMA magazine — analysis, tools and learning with no payment up front.

Free registration, no card — trial full access, then the free plan

Want the full ENTA analysis with all layers and live data? Open ENTA detail →

Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.

⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.

Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]